secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001730463-24-000129
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Autolus' AUCATZYL (obe-cel) for adult r/r B-ALL; no REMS required
------------------------------------------------------------------------------

- Approval based on FELIX trial: 63% overall complete remission (CR/CRi) in efficacy-evaluable patients (n=65); median DOR 14.1 months.
- Only 3% Grade ≥3 CRS and 7% Grade ≥3 ICANS; no REMS program required by FDA.
- Boxed warning for CRS, neurologic toxicities, secondary hematological malignancies; T-cell malignancies risk noted.
- Commercial manufacturing at Nucleus in Stevenage, UK; Cardinal Health as U.S. distribution partner.
- EU and UK MAAs under review; company to host conference call Nov 11.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000129/0001730463-24-000129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000129/autl-20241108.htm
  HTML page:      https://secwatch.observer/filing/0001730463-24-000129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer